Some previous studies showed abnormal pathological and vascular changes in the retina of patients with Alzheimer’s disease (AD). However, whether retinal microvascular density is a diagnostic indicator for AD remains unclear.
Objective:
This study evaluated the macular vessel density (m-VD) in the superficial capillary plexus and fovea avascular zone (FAZ) area in AD, explored their correlations with clinical parameters, and finally confirmed an optimal machine learning model for AD diagnosis.
Methods:
77 patients with AD and 145 healthy controls (HCs) were enrolled. The m-VD and the FAZ area were measured using optical coherence tomography angiography (OCTA) in all participants. Additionally, AD underwent neuropsychological assessment, brain magnetic resonance imaging scan, cerebrospinal fluid (CSF) biomarker detection, and APOE ɛ4 genotyping. Finally, the performance of machine learning algorithms based on the OCTA measurements was evaluated by Python programming language.
Results:
The m-VD was noticeably decreased in AD compared with HCs. Moreover, m-VD in the fovea, superior inner, inferior inner, nasal inner subfields, and the whole inner ring declined significantly in mild AD, while it was more serious in moderate/severe AD. However, no significant difference in the FAZ was noted between AD and HCs. Furthermore, we found that m-VD exhibited a significant correlation with cognitive function, medial temporal atrophy and Fazekas scores, and APOE ɛ4 genotypes. No significant correlations were observed between m-VD and CSF biomarkers. Furthermore, results revealed the Adaptive boosting algorithm exhibited the best diagnostic performance for AD.
Conclusion:
Macular vascular density could serve as a diagnostic biomarker for AD.
BloomGS (2014) Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol71, 505–508.
2.
Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement12, 459–509.
3.
VlassenkoAG, McCueL, JasielecMS, SuY, GordonBA, XiongC, HoltzmanDM, BenzingerTL, MorrisJC, FaganAM (2016) Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann Neurol80, 379–387.
4.
GauthierS, Rosa-NetoP, MoraisJA, WebsterC (2021) . Alzheimer’s Disease International. World Alzheimer Report 2021. Journey through the diagnosis of dementia–London.
5.
de la TorreJ (2018) The vascular hypothesis of Alzheimer’s disease: A key to preclinical prediction of dementia using neuroimaging. J Alzheimers Dis63, 35–52.
6.
KlohsJ (2019) An integrated view on vascular dysfunction in Alzheimer’s disease. Neurodegener Dis19, 109–127.
7.
NelsonAR, SweeneyMD, SagareAP, ZlokovicBV (2016) Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim Biophys Acta1862, 887–900.
8.
ZlokovicBV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci12, 723–738.
9.
Di MarcoLY, VenneriA, FarkasE, EvansPC, MarzoA, FrangiAF (2015) Vascular dysfunction in the pathogenesis of Alzheimer’s disease–A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis82, 593–606.
10.
PattonN, AslamT, MacgillivrayT, PattieA, DearyIJ, DhillonB (2005) Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: A rationale based on homology between cerebral and retinal microvasculatures. J Anat206, 319–348.
11.
Koronyo-HamaouiM, KoronyoY, LjubimovAV, MillerCA, KoMK, BlackKL, SchwartzM, FarkasDL (2011) Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive optical imaging of retinal plaques in a mouse model. Neuroimage54, S204–217.
La MorgiaC, Ross-CisnerosFN, KoronyoY, HannibalJ, GallassiR, CantalupoG, SambatiL, PanBX, TozerKR, BarboniP, ProviniF, AvanziniP, CarbonelliM, PelosiA, ChuiH, LiguoriR, BaruzziA, Koronyo-HamaouiM, SadunAA, CarelliV (2016) Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol79, 90–109.
14.
GrimaldiA, PediconiN, OieniF, PizzarelliR, RositoM, GiubettiniM, SantiniT, LimatolaC, RuoccoG, RagozzinoD, Di AngelantonioS (2019) Neuroinflammatory processes, A1 astrocyte activation and protein aggregation in the retina of Alzheimer’s disease patients, possible biomarkers for early diagnosis. Front Neurosci13, 925.
15.
den Haan J, MorremaTHJ, VerbraakFD, de Boer JF, ScheltensP, RozemullerAJ, BergenAAB, BouwmanFH, HoozemansJJ (2018) Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun6, 147.
16.
BerishaF, FekeGT, TrempeCL, McMeelJW, SchepensCL (2007) Retinal abnormalities in early Alzheimer’s disease. Invest Ophthalmol Vis Sci48, 2285–2289.
17.
FrostS, KanagasingamY, SohrabiH, VignarajanJ, BourgeatP, SalvadoO, VillemagneV, RoweCC, MacaulaySL, SzoekeC, EllisKA, AmesD, MastersCL, Rainey-SmithS, MartinsRN, AIBL Research Group (2013) Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Transl Psychiatry3, e233.
18.
CheungCY, OngYT, IkramMK, OngSY, LiX, HilalS, CatindigJA, VenketasubramanianN, YapP, SeowD, ChenCP, WongTY (2014) Microvascular network alterations in the retina of patients with Alzheimer’s disease. Alzheimers Dement10, 135–142.
ZhangYS, ZhouN, KnollBM, SamraS, WardMR, WeintraubS, FawziAA (2019) Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnestic mild cognitive impairment and early Alzheimer’s disease on optical coherence tomography angiography. PLoS One14, e0214685.
21.
van de Kreeke JA, NguyenHT, KonijnenbergE, TomassenJ, den Braber A, Ten Kate M, YaqubM, van Berckel B, LammertsmaAA, BoomsmaDI, TanSH, VerbraakF, VisserPJ (2020) Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br J Ophthalmol104, 157–161.
YoonSP, GrewalDS, ThompsonAC, PolascikBW, DunnC, BurkeJR, FekratS (2019) Retinal microvascular and neurodegenerative changes in Alzheimer’s disease and mild cognitive impairment compared with control participants. Ophthalmol Retina3, 489–499.
29.
den Haan J, van de Kreeke JA, van Berckel BN, BarkhofF, TeunissenCE, ScheltensP, VerbraakFD, BouwmanFH (2019) Is retinal vasculature a biomarker in amyloid proven Alzheimer’s disease? . Alzheimers Dement (Amst)11, 383–391.
30.
QuerquesG, BorrelliE, SacconiR, De Vitis L, LeocaniL, SantangeloR, MagnaniG, ComiG, BandelloF (2019) Functional and morphological changes of the retinal vessels in Alzheimer’s disease and mild cognitive impairment. Sci Rep9, 63.
31.
HoCY, TronosoJC, KnoxD, StarkW, EberhartCG (2014) Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer’s and Parkinson’s disease patients. Brain Pathol24, 25–32.
32.
WilliamsEA, McGuoneD, FroschMP, HymanBT, LaverN, Stemmer-RachamimovA (2017) Absence of Alzheimer disease neuropathologic changes in eyes of subjects with Alzheimer disease. J Neuropathol Exp Neurol76, 376–383.
33.
AoC, JinS, DingH, ZouQ, YuL (2020) Application and development of artificial intelligence and intelligent disease diagnosis. Curr Pharm Des26, 3069–3075.
34.
GunasekeranDV, TingDSW, TanGSW, WongTY (2020) Artificial intelligence for diabetic retinopathy screening, prediction and management. Curr Opin Ophthalmol31, 357–365.
35.
MakinoM, YoshimotoR, OnoM, ItokoT, KatsukiT, KosekiA, KudoM, HaidaK, KurodaJ, YanagiyaR, SaitohE, HoshinagaK, YuzawaY, SuzukiA (2019) Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning. Sci Rep9, 11862.
36.
RommEL, TsigelnyIF (2020) Artificial intelligence in drug treatment. Annu Rev Pharmacol Toxicol60, 353–369.
37.
SilverbergN, ElliottC, RyanL, MasliahE, HodesR (2018) NIA commentary on the NIA-AA Research Framework: Towards a biological definition of Alzheimer’s disease. Alzheimers Dement14, 576–578.
38.
KatzmanR, ZhangMY, Ouang-Ya-Qu, WangZY, LiuWT, YuE, WongSC, SalmonDP, GrantI (1988) A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol41, 971–978.
39.
KorfES, WahlundLO, VisserPJ, ScheltensP (2004) Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology63, 94–100.
40.
PasquierF, LeysD, WeertsJG, Mounier-VehierF, BarkhofF, ScheltensP (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol5, 268–272.
41.
KoedamEL, LehmannM, van der Flier WM, ScheltensP, PijnenburgYA, FoxN, BarkhofF, WattjesMP (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol21, 2618–2625.
42.
FazekasF, KleinertR, OffenbacherH, SchmidtR, KleinertG, PayerF, RadnerH, LechnerH (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology43, 1683–1689.
WuJ, ZhangX, AzhatiG, LiT, XuG, LiuF (2020) Retinal microvascular attenuation in mental cognitive impairment and Alzheimer’s disease by optical coherence tomography angiography. , e781-e. Acta Ophthalmol98, 787.
45.
van de Kreeke JA, NguyenHT, KonijnenbergE, TomassenJ, den Braber A, Ten Kate M, YaqubM, van Berckel B, LammertsmaAA, BoomsmaDI, TanSH, VerbraakF, VisserPJ (2020) . Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br J Ophthalmol104, 157–161.
46.
BrownWR, ThoreCR (2011) Review: Cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol37, 56–74.
47.
VandenabeeleM, VeysL, LemmensS, HadouxX, GeldersG, MasinL, SerneelsL, TheunisJ, SaitoT, SaidoTC, JayapalaM, De Boever P, De Strooper B, StalmansI, van Wijngaarden P, MoonsL, De Groef L (2021) The App (NL-G-F) mouse retina is a site for preclinical Alzheimer’s disease diagnosis and research. Acta Neuropathol Commun9, 6.
48.
ShiH, KoronyoY, RentsendorjA, RegisGC, SheynJ, FuchsDT, KramerovAA, LjubimovAV, DumitrascuOM, RodriguezAR, BarronE, HintonDR, BlackKL, MillerCA, MirzaeiN, Koronyo-HamaouiM (2020) Identification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina. Acta Neuropathol139, 813–836.
49.
LiM, YangY, JiangH, GregoriG, RoismanL, ZhengF, KeB, QuD, WangJ (2017) Retinal microvascular network and microcirculation assessments in high myopia. Am J Ophthalmol174, 56–67.
50.
ZabelP, KaluznyJJ, Wilkosc-DebczynskaM, Gebska-ToloczkoM, SuwalaK, ZabelK, ZaronA, KucharskiR, AraszkiewiczA (2019) Comparison of retinal microvasculature in patients with Alzheimer’s disease and primary open-angle glaucoma by optical coherence tomography angiography. Invest Ophthalmol Vis Sci60, 3447–3455.
51.
LiZB, LinZJ, LiN, YuH, WuYL, ShenX (2021) Evaluation of retinal and choroidal changes in patients with Alzheimer’s type dementia using optical coherence tomography angiography. Int J Ophthalmol14, 860–868.
52.
LahmeL, EsserEL, MihailovicN, SchubertF, LauermannJ, JohnenA, EterN, DuningT, AlnawaisehM (2018) Evaluation of ocular perfusion in Alzheimer’s disease using optical coherence tomography angiography. J Alzheimers Dis66, 1745–1752.
53.
WangX, ZhaoQ, TaoR, LuH, XiaoZ, ZhengL, DingD, DingS, MaY, LuZ, XiaoY (2020) Decreased retinal vascular density in Alzheimer’s disease (AD) and mild cognitive impairment (MCI): An optical coherence tomography angiography (OCTA) study. Front Aging Neurosci12, 572484.
54.
ZhangYS, ZhouN, KnollBM, SamraS, WardMR, WeintraubS, FawziAA (2019) Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnestic mild cognitive impairment and early Alzheimer’s disease on optical coherence tomography angiography. PLoS One14, e0214685.
55.
LindermanRE, MuthiahMN, OmobaSB, LittsK, TarimaS, VisotckyA, KimJE, CarrollJ (2018) Variability of foveal avascular zone metrics derived from optical coherence tomography angiography images. Transl Vis Sci Technol7, 20.
56.
Wagner-SchumanM, DubisAM, NordgrenRN, LeiY, OdellD, ChiaoH, WehE, FischerW, SulaiY, DubraA, CarrollJ (2011) Race- and sex-related differences in retinal thickness and foveal pit morphology. Invest Ophthalmol Vis Sci52, 625–634.
57.
OmettoG, MontesanoG, ChakravarthyU, KeeF, HoggRE, CrabbDP, (2021) Fast 3-dimensional estimation of the Foveal Avascular Zone from OCTA[C]. IEEE International Instrumentation and Measurement Technology Conference (I2MTC).
58.
KimCM, AlvaradoRL, StephensK, WeyHY, WangDJJ, LeritzEC, SalatDH (2020) Associations between cerebral blood flow and structural and functional brain imaging measures in individuals with neuropsychologically defined mild cognitive impairment. Neurobiol Aging86, 64–74.
59.
JellingerKA (2013) Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci5, 17.
60.
AntesR, Salomon-ZimriS, BeckSC, Garcia Garrido M, LivnatT, MaharshakI, KadarT, SeeligerM, WeinbergerD, MichaelsonDM (2015) VEGF mediates ApoE4-induced neovascularization and synaptic pathology in the choroid and retina. Curr Alzheimer Res12, 323–334.
61.
SchultzN, BymanE, Netherlands Brain B, WennstromM (2020) Levels of retinal amyloid-beta correlate with levels of retinal IAPP and hippocampal amyloid-beta in neuropathologically evaluated individuals. J Alzheimers Dis73, 1201–1209.
